ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
9.93
-0.04 (-0.40%)
At close: Dec 5, 2025, 4:00 PM EST
9.62
-0.31 (-3.12%)
After-hours: Dec 5, 2025, 5:01 PM EST
ARS Pharmaceuticals Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Dec '25 Dec 5, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Market Capitalization | 982 | 1,025 | 526 | 800 | - | - |
| Market Cap Growth | -26.71% | 94.90% | -34.23% | - | - | - |
| Enterprise Value | 863 | 821 | 284 | 839 | - | - |
| Last Close Price | 9.93 | 10.55 | 5.48 | 8.53 | - | - |
| PE Ratio | - | 128.20 | - | - | - | - |
| PS Ratio | 6.83 | 11.50 | 17535.50 | 607.80 | - | - |
| PB Ratio | 6.65 | 3.99 | 2.28 | 2.93 | - | - |
| P/TBV Ratio | 7.39 | 4.12 | 2.29 | 2.93 | - | - |
| P/FCF Ratio | - | 78.96 | - | - | - | - |
| P/OCF Ratio | - | 75.68 | - | - | - | - |
| EV/Sales Ratio | 6.05 | 9.21 | 9483.00 | 637.20 | - | - |
| EV/FCF Ratio | - | 63.20 | - | - | - | - |
| Debt / Equity Ratio | 1.15 | 0.27 | 0.00 | 0.00 | 0.20 | 1.40 |
| Debt / FCF Ratio | - | 5.35 | - | - | - | 1.10 |
| Asset Turnover | 0.48 | 0.31 | 0 | 0.01 | 0.13 | - |
| Quick Ratio | 6.41 | 13.79 | 95.80 | 50.59 | 7.34 | 3.03 |
| Current Ratio | 6.66 | 14.26 | 96.92 | 51.01 | 7.42 | 3.21 |
| Return on Equity (ROE) | -45.92% | 3.28% | -21.59% | -21.84% | -77.93% | - |
| Return on Assets (ROA) | -19.22% | -0.66% | -16.40% | -12.56% | -27.68% | - |
| Return on Capital (ROIC) | -21.88% | -0.69% | -16.73% | -13.17% | -34.25% | - |
| Return on Capital Employed (ROCE) | -28.20% | -0.90% | -29.30% | -12.50% | -36.50% | -2.60% |
| Earnings Yield | -8.15% | 0.78% | -10.33% | -4.34% | - | - |
| FCF Yield | -8.76% | 1.27% | -11.30% | -5.04% | - | - |
| Buyback Yield / Dilution | -1.59% | -7.54% | -138.30% | -38.39% | -42.81% | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.